Shares Outstanding Shares Outstanding n/a Close	152.56M
Shares Change (YoY) Shares Change (YoY) n/a Close	1.11%
Shares Change (QoQ) Shares Change (QoQ) n/a Close	0.15%
Owned by Institutions (%) Owned by Institutions (%) n/a Close	75.21%
Shares Floating Shares Floating n/a Close	151.14M
Failed to Deliver (FTD) Shares Failed to Deliver (FTD) Shares n/a Close	14
FTD / Avg. Volume FTD / Avg. Volume n/a Close	n/a

Short Selling Information

The latest short interest is 33.96M, so 22.26% of the outstanding shares have been sold short.

Short Interest Short Interest n/a Close	33.96M
Short % of Shares Out Short % of Shares Out n/a Close	22.26%
Short % of Float Short % of Float n/a Close	28.94%
Short Ratio (days to cover) Short Ratio (days to cover) n/a Close	37.97

Valuation Ratios

The PE ratio is -17.18 and the forward PE ratio is 28.79. Heron Therapeutics's PEG ratio is 0.19.

PE Ratio PE Ratio n/a Close	-17.18
Forward PE Forward PE n/a Close	28.79
PS Ratio PS Ratio n/a Close	1.62
Forward PS Forward PS n/a Close	1
PB Ratio PB Ratio n/a Close	-6.93
P/FCF Ratio P/FCF Ratio n/a Close	-9.62
PEG Ratio PEG Ratio n/a Close	0.19

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Heron Therapeutics.

EV / Sales EV / Sales n/a Close	n/a
EV / EBITDA EV / EBITDA n/a Close	n/a
EV / EBIT EV / EBIT n/a Close	n/a
EV / FCF EV / FCF n/a Close	n/a

Financial Position

The company has a current ratio of 2.29, with a Debt / Equity ratio of -5.28.

Current Ratio Current Ratio n/a Close	2.29
Quick Ratio Quick Ratio n/a Close	1.7
Debt / Equity Debt / Equity n/a Close	-5.28
Debt / EBITDA Debt / EBITDA n/a Close	-35.16
Debt / FCF Debt / FCF n/a Close	-7.33
Interest Coverage Interest Coverage n/a Close	-1.91

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity Return on Equity n/a Close	n/a
Return on Assets Return on Assets n/a Close	n/a
Return on Invested Capital Return on Invested Capital n/a Close	n/a
Revenue Per Employee Revenue Per Employee n/a Close	$1,182,663.93
Profits Per Employee Profits Per Employee n/a Close	$-111,311.48
Employee Count Employee Count n/a Close	122
Asset Turnover Asset Turnover n/a Close	0.62
Inventory Turnover Inventory Turnover n/a Close	0.73

Taxes

Income Tax Income Tax n/a Close	n/a
Effective Tax Rate Effective Tax Rate n/a Close	0%

Stock Price Statistics

The stock price has increased by -46.67% in the last 52 weeks. The beta is 1.17, so Heron Therapeutics's price volatility has been higher than the market average.

Beta Beta n/a Close	1.17
52-Week Price Change 52-Week Price Change n/a Close	-46.67%
50-Day Moving Average 50-Day Moving Average n/a Close	2.03
200-Day Moving Average 200-Day Moving Average n/a Close	1.86
Relative Strength Index (RSI) Relative Strength Index (RSI) n/a Close	44.89
Average Volume (20 Days) Average Volume (20 Days) n/a Close	1,484,793

Income Statement

In the last 12 months, Heron Therapeutics had revenue of 144.28M and earned -13.58M in profits. Earnings per share was -0.09.

Revenue Revenue n/a Close	144.28M
Gross Profit Gross Profit n/a Close	105.64M
Operating Income Operating Income n/a Close	-11.53M
Net Income Net Income n/a Close	-13.58M
EBITDA EBITDA n/a Close	-5.06M
EBIT EBIT n/a Close	-7.55M
Earnings Per Share (EPS) Earnings Per Share (EPS) n/a Close	-0.09

Full Income Statement

Balance Sheet

The company has 25.8M in cash and 177.76M in debt, giving a net cash position of -151.96M.

Cash & Cash Equivalents Cash & Cash Equivalents n/a Close	25.8M
Total Debt Total Debt n/a Close	177.76M
Net Cash Net Cash n/a Close	-151.96M
Retained Earnings Retained Earnings n/a Close	-1.92B
Total Assets Total Assets n/a Close	235.75M
Working Capital Working Capital n/a Close	124.28M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -22.53M and capital expenditures -1.71M, giving a free cash flow of -24.23M.

Operating Cash Flow Operating Cash Flow n/a Close	-22.53M
Capital Expenditures Capital Expenditures n/a Close	-1.71M
Free Cash Flow Free Cash Flow n/a Close	-24.23M
FCF Per Share FCF Per Share n/a Close	-0.16

Full Cash Flow Statement

Margins

Gross margin is 73.21%, with operating and profit margins of -7.99% and -9.41%.

Gross Margin Gross Margin n/a Close	73.21%
Operating Margin Operating Margin n/a Close	-7.99%
Pretax Margin Pretax Margin n/a Close	-9.41%
Profit Margin Profit Margin n/a Close	-9.41%
EBITDA Margin EBITDA Margin n/a Close	-3.5%
EBIT Margin EBIT Margin n/a Close	-7.99%
FCF Margin FCF Margin n/a Close	-16.8%

Dividends & Yields

HRTX does not appear to pay any dividends at this time.

Dividend Per Share Dividend Per Share n/a Close	n/a
Dividend Yield Dividend Yield n/a Close	n/a
Dividend Growth (YoY) Dividend Growth (YoY) n/a Close	n/a
Payout Ratio Payout Ratio n/a Close	n/a
Earnings Yield Earnings Yield n/a Close	n/a
FCF Yield FCF Yield n/a Close	n/a

Dividend Details

Analyst Forecast

The average price target for HRTX is $5, which is 160.4% higher than the current price. The consensus rating is "Buy".

Price Target Price Target n/a Close	$5
Price Target Difference Price Target Difference n/a Close	160.4%
Analyst Consensus Analyst Consensus n/a Close	Buy
Analyst Count Analyst Count n/a Close	2

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value Lynch Fair Value n/a Close	n/a
Lynch Upside Lynch Upside n/a Close	n/a
Graham Number Graham Number n/a Close	n/a
Graham Upside Graham Upside n/a Close	n/a

Stock Splits

The last stock split was on Jan 13, 2014. It was a backward split with a ratio of 1:20.

Last Split Date Last Split Date n/a Close	Jan 13, 2014
Split Type Split Type n/a Close	backward
Split Ratio Split Ratio n/a Close	1:20

Scores

Altman Z-Score Altman Z-Score n/a Close	-9.49
Piotroski F-Score Piotroski F-Score n/a Close	2